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Nanomedicine has demonstrated the
potential of nanotechnology in treating
diseases by selectively targeting patho-
genic cells and releasing their cargo on
site, but the complexity of molecular en-
gineering such drug-delivery vehicles im-
pedes their broad application and clinical
translation. New methodologies to gen-
erate more advanced and intelligent sys-
tems are required.
Bottom-up synthetic biology, empow-Creating a magic bullet that can selectively kill cancer cells while sparing nearby
healthy cells remains one of the most ambitious objectives in pharmacology.
Nanomedicine, which relies on the use of nanotechnologies to fight disease,
was envisaged to fulfill this coveted goal. Despite substantial progress, the
structural complexity of therapeutic vehicles impedes their broad clinical
application. Novel modular manufacturing approaches for engineering program-
mable drug carriers may be able to overcome some fundamental limitations of
nanomedicine. We discuss how bottom-up synthetic biology principles,
empowered by microfluidics, can palliate current drug carrier assembly limita-
tions, and we demonstrate how such a magic bullet could be engineered from
the bottom up to ultimately improve clinical outcomes for patients.ered bymicrofluidics, allows the concep-
tion of multifunctional cell-mimicking
structures – such as synthetic exosomes
– that showcase its ability to create so-
phisticated systems.
Recently, considerable progress has
been made towards the assembly of
complex structures that can dynamically
release therapeutics, sustain protein bio-
synthesis, and sense and interact with
the nearby environment. These function-
alities will propel the creation of ad-
vanced drug-delivery platforms.
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Paul Ehrlich, considered to be the pioneer and founder of modern chemotherapy, envisaged a
therapeutic capable of directly interreacting with its intended disease-causing cellular structure
while remaining harmless to the surrounding healthy cell population. Depicted as a magic bullet,
his idea has greatly influenced and fascinated various fields of science for more than a century [1].
Among them, the field of nanomedicine (see Glossary) –which relies on nanotechnologies to im-
prove passive and active accumulation of drugs nearby target pathogens or cell populations –
was expected to achieve this highly coveted goal. Despite its major focus on oncology,
nanomedicine has also triggered the engineering of an arsenal of novel nanotechnologies and
functionalization strategies. Overall, these innovations have resulted in a variety of enhanced
bio- and physico-chemical properties for inorganic-, polymer-, and lipid-based nanometric
carriers.
Despite recent progress, nanomedicine is often synonymous with modest clinical translation and
remains the focus of significant debate (as reviewed extensively [2–4]). Isolated examples of suc-
cess, namely Doxil® [5,6], Abraxane® [7], and most recently Onpattro® [8], are few, and greater
success in the design of nanoformluated drugs in the near future remains unlikely because several
barriers will need to be overcome to achieve effective and specific delivery of drug-loaded
carriers.
Targeted delivery of therapeutics may be organized into different levels, referred to as primary,
secondary, and tertiary targeting. These levels are defined by the degree of target specificity
and control over release dynamics, which increase along the chain [9]. This targeting hierarchy
is summarized and illustrated in Boxes 1 and 2, and also in Figure 1. Briefly, primary targeting,
or the targeting of specific organs, is highly size-dependent since smaller nanomaterials are ex-
pected to transit through the blood–brain barrier [10–12], or navigate through the fenestrated
vessels in the liver endothelium or tumor environment more easily [13]. However, this size discrim-
ination may be circumvented by meticulously engineering the physicochemical properties of the
carrier such as molecular composition, surface charge, and mechanical properties (Box 1). ToTrends in Biotechnology, May 2021, Vol. 39, No. 5 https://doi.org/10.1016/j.tibtech.2020.08.002 445
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Glossary
Bottom-up synthetic biology: an
emerging interdisciplinary scientific field
that aims to create minimalistic cellular
replicates through the precise assembly
of molecular building blocks.
Droplet-based microfluidics:
microfluidic platforms that allow the
generation and manipulation of discrete
droplets (femto- to pico-liter volume) in
an immiscible carrier fluid. These
platforms enable the utilization of various
modules to manipulate each individual
droplet with high precision.
Exosomes: a subtype of extracellular
vesicles that are produced by various
cell types. Owing to the mechanism of
their biogenesis, exosomes harbor a
variety of membrane-bound and soluble
constituents – such as cytosolic proteins
and RNAs – from their cellular origin.
Common membrane-bound proteins
include the tetraspanins, such as CD9,
CD63, and CD81; MHC I, MHC II;
membrane-transport and -fusion
proteins (Rab, GTPases); and lipid raft-
associated proteins [67]. This intricate
molecular composition gives exosomes
the ability to activate multiple signaling
pathways that, in concert, initiate, drive,
and regulate the single and collective
responses of tissues. These responses
in turn underlie nearly all facets of
Box 1. The Targeting Hierarchy of Cell-Selective Drug Delivery: Primary Targeting
Primary targeting implies the specific, in most cases passive, accumulation of therapeutics in the desired organ where dis-
ease-causing cells reside (see Figure 1, left in main text). So far, primary targeting has mostly focused on organs that have
high levels of mononuclear phagocyte system (MPS components, lower blood velocity (i.e., low blood pressure), and small
blood capillary diameters. These characteristics, which are common for the liver, spleen, kidney, and lymph nodes, lead to
an increase in the passive accumulation of therapeutic carriers in these organs. Consequently, primary targeting of these
organs enabled the acquisition of important trends and criteria that needs to be considered when assembling a drug-de-
livery system. To reach the desired targeted site, a drug-delivery systemmust have a long circulation time inside the blood-
stream, meaning that the carrier must be able to evade the immune system, minimize opsonization (i.e., nonspecific
adsorption of serum proteins onto the carrier surface), and, most importantly, evade the MPS. The latter is the greatest
obstacle to successful primary targeting. To put it in numbers, the MPS has been made responsible for the fact that only
0.1% of nanomedicines accumulate at the target site [14]. Multiple interdependent parameters modulate the interaction of
a drug carrier with the MPS and affect its biodistribution and accumulation during its journey towards a specific organ
[68,69]. These parameters include surface charge, particle size, geometry, porosity, chemical composition, and mechan-
ical properties. All of these need to be optimized to maximize delivery efficiency and thus therapeutic outcome. Further-
more, in the case of cancer therapy, additional optimization to account for tumor type and stage needs to be included
[70,71].
Typically, the targeting efficiency of specific organs – such as the brain and the tumor environment – is highly size-depen-
dent. Despite the general observation that smaller delivery vehicles lead to higher uptake, various reports also showed that
size might be less important than other surface properties [72,73]. For example, the transport of larger carriers across the
blood–brain barrier was facilitated by either conjugating lipophilic moieties such as apolipoprotein E [74,75] or by adjusting
charge polarity and molecular composition [76]. For instance, lipid nanoparticles were recently reported to enable specific
charge-mediated targeting to the lungs, liver, and spleen by changing their lipid composition [77]. These observations
highlight the interdependence of physical parameters such as size, charge, and mechanics.
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moieties to discriminate and selectively interact with the targeted cellular population – such as
cancer cells – that are typically surrounded by a plethora of healthy cellular entities (Box 2). To
this aim, functional groups sensitive to local endogenous changes – such as pH, redox states,
or enzyme overexpression – are employed to promote interaction of the carrier with the targetmulticellular organisms, underscoring
the central physiological role of
exosome-mediated intercellular
communication and their involvement in
a wide variety of disease states. These
natural attributes thus make exosomes,
a priori, ideal natural carriers for drug-
delivery applications.
Giant unilamellar vesicles (GUVs):
micrometer-sized lipid-based vesicles
that are commonly employed as an
artificial cell-membrane mimetics.
Microfluidics: a technology that relies
on the fabrication of microscopic
channels in a polymeric substrate (i.e.,
PDMS) or the use of glass microcapillary
to precisely manipulate various fluids at
the picoliter scale.
Nanomedicine: as a broad definition,
nanomedicine implies the use of various
forms of nanotechnology to diagnose or
treat (or a combination of both referred
to as theranostics) different health
diseases. More specifically, but not
exclusively, nanomedicine has received
significant attention in the field of
oncology owing to the enhanced
physicochemical and biochemical
properties conferred by nanomaterials.
Box 2. The Targeting Hierarchy of Cell-Selective Drug Delivery: Secondary and Tertiary Targeting
Secondary targeting brings up additional and more intricate challenges compared to primary targeting. First, cell type-
specificity needs to be established as part of the carrier to selectively target disease-causing cells, which are usually
surrounded by several distinct types of healthy cells. This selectivity is typically introduced by incorporating various molec-
ular receptors such as antibodies, aptamers, peptides, or proteins on the carrier. Upon recognition with the targeted mo-
lecular target, the interactionmay result in a prolonged lingering of the carrier in close proximity to the target cell population.
Ultimately, this selective interaction will promote the internalization or fusion of the carrier with the target cell membrane.
Once internalized, the carrier must release its therapeutic cargo.
In addition to selective interaction, the drug carrier must be stimulus-responsive. The molecular composition of the imme-
diate extracellular environment is often determined and altered by the cellular phenotype [78]. Common endogenous bio-
chemical changes in proximity to tumor cells include a decrease in the extracellular pH, a change in the redox potential
owing to hypoxia promoted by poor vascularization of the tumor environment, and increased expression of matrix
metallopeptidases. Accordingly, recent studies have worked on improving drug carrier formulations to integrate ionizable
motifs that undergo chargemodulation as a function of pH [79–81]. The chargemodulation triggered by the ionizable motif
can promote the destabilization of the carrier. This can either increase the permeability of the carrier, thereby facilitating the
ability to release its cargo on site [79,82], or enhance its fusogenicity to promote fusion with the cancer cell membrane [83].
Increased fusogenicity allows the intracellular delivery of therapeutics and minimizes drug toxicity to neighboring healthy
cells.
Following carrier internalization, tertiary targeting requires the efficient release of its cargo and selective interaction with the
intracellular target structure, for example, specific organelles, RNAs, DNAs, or ribosomes (Box 1). The intracellular fate of
the drug is directly dictated by its capacity to overcome additional biological barriers. Major intracellular obstacles include
the entrapment of therapeutics in endosomes and lysosomes – organelles that degrade foreign materials through the ac-
tion of enzymes and low intraluminal pH [84]. Therefore, carriers need to recognize specific surface receptors to allow them
to distinguish between healthy and malignant cells, and perceive subtle changes in the local extracellular environment.
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Surfactants: amphiphilic molecules
(such as lipids and block-o-polymers)
that exhibit amphiphilic interactions with
both an oil (organic) phase and an
aqueous phase. Lipids or block-o-
polymers can be supplemented in the oil
phase of a droplet-based microfluidics
system to stabilize water-in-oil droplets,
thus enabling their manipulation with
ease. In addition, surfactants can be
supplemented in the aqueous phase to
further stabilize lipid-based vesicles or
promote surface dewetting by altering
the surface and interfacial tension.
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OPEN ACCESScell population, facilitate its internalization, and ultimately release its molecular payload
intracellularly.
However, a central question remains open: is the current focus on nanoscale formulations neces-
sary to improve the clinical performance of drug-delivery systems? This question builds on the
observation that a restricted number of nanomaterials have provided only minimal benefit to can-
cer therapy over the past decades. This mostly reflects their poor efficacy in improving delivery
efficiency [14] as well as the structural and chemical complexity of the biological barriers that
need to be overcome for efficient drug delivery [15–17]. Conversely, a growing body of research
supports a shift of focus. For example, preliminary results showed a specific potential for primary
targeting of the brain by delivering rivastigmine to treat Alzheimer’s disease via oral and intraper-
itoneal administration of micron-scale liposomes ranging from 3 to 10 μm in diameter [18,19].
These observations show that micron-scale lipid carriers, such as giant unilamellar vesicles
(GUVs), might have great potential for primary targeting. An additional advantage of micron-
scale lipid-based vehicles is that the cell–carrier interaction can be modulated by incorporating
various ligands, or repellant motifs, while also incorporating stimulus-sensitive motives for im-
proved fusogenicity and internalization [20]. Moreover, several recent studies have demonstrated
that micron-scale lipid-based vesicles can interact with cells and their intracellular components
[21] as well as directly release therapeutics inside the cytoplasm [22]. These examples highlight
that micron-scale vesicles can reach specific organs, be internalized by cells, and interact with in-
tracellular constituents.
Expanding the selection of tools to include micron-sized materials and systems incorporating
multi-scale compartments opens up entirely new possibilities for the generation of more ad-
vanced carriers. However, prerequisite for this ambitious task is that the carriers need to have a
long circulation time, minimal passive release of its cargo during transit, and evade both the im-
mune system and mononuclear phagocyte system (MPS) [23]. Considering all these criteria, nat-
ural living cells may represent the ideal drug-delivery system owing to their ability to transport
therapeutics and minimally interact with the immune system and MPS by acting as nonforeign
carriers. Consequently, the use of naturally occurring entities or naturally derived systems to de-
liver therapeutics has become a growing focus of research. First attempts towards more natural
systems have included the use of hybrid materials based on either isolated cell structures or on
fully synthetic motives to improve drug-delivery efficiency. Following recent technical innovations
in the field of bottom-up synthetic biology – where mostly GUV-based artificial cell-like com-
partments have been exploited – improved cell mimicry could be engineered to further improve
drug delivery. Such a paradigm shift from nano- to micron-sized materials would also allow the
utilization of microfluidic technologies (Figure 2, Key Figure) that offer the notable advantages
of excellent reproducibility, controllability, complexity, and production capability. In particular,
droplet-based microfluidics is ideally suited to engineer micron-scale complex lipid vesicles
through sequential and precise manipulation of water-in-oil droplets [20,21,24–26].
This review describes the potential advantages of employing bottom-up synthetic biology princi-
ples for the construction of advanced drug-delivery carriers. We illustrate how naturally derived
systems can facilitate and improve drug delivery. In addition, we present examples that apply bot-
tom-up synthetic biology principles to generate bioinspired synthetic systemswith well-controlled
biophysical and biochemical properties for advanced drug release. We also describe the gener-
ation of complex systems with various microfluidic platforms, and critically evaluate the draw-
backs and challenges that these platforms must overcome before successful clinical
translation. Finally, we present a short perspective on the potential of the advanced bottom-up
assembly of lipid-based carriers for improved therapies.Trends in Biotechnology, May 2021, Vol. 39, No. 5 447
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Figure 1. Hierarchy of Targeted Drug Delivery. To achieve a higher efficiency of drug delivery to disease-causing cells, the therapeutic carrier is engineered to
maximize its passive accumulation in the primary target organ. This can be facilitated by a suitable means of administration (shown on the left). Therapeutic carriers are
preferably administrated intravenously, upon which the secondary targeting journey towards the appropriate cell type begins. During transit, the carriers steer towards
the disease-causing cells while evading various histological barriers such as MPS components, non-specific adsorption of serum proteins, and the immune system,
and then extravasate from the blood vessel (middle). The therapeutic carriers then need to selectively interact with the nearby target cell population, ultimately leading
to their adsorption or internalization. Once internalized, tertiary targeting is initiated. The carriers need to evade endosomes before finally releasing the therapeutic into
the cytosol of the designated cell. The final release of the therapeutic, which targets only a specific organelle within the cytosol, from the carrier is influenced by various
endogenous or external stimuli (right).
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Extracellular vesicles (EVs) are lipid-based vesicles that are secreted by various cell types and
range from 100 nm to several microns in size. EVs have recently gained significant attention as
therapeutic vehicles [27] and biomarkers [28,29] owing to their pivotal roles in intercellular com-
munication and their involvement in various disease states. For instance, encapsulation of pacli-
taxel into EVs can achieve both increased accumulation and improved targeted delivery to cells
[30,31]. To benefit from the qualities of advanced EVs in terms of targeting, Rayamajhi and col-
leagues developed hybrid exosomes (HEs) by fusing synthetic liposomes with cell-extracted
exosomes [32]. The HEs produced presented various membrane proteins, such as CD63,
CD81, and CD9 (see Exosomes in the Glossary), derived from macrophage-derived exosomal
preparations. HE application was associated with both improved cancer targeting and cell inter-
nalization. In addition, Liang and coworkers recently demonstrated the importance of the me-
chanical properties of doxorubicin-loaded EVs for drug delivery to tumor cells [33]. The authors
report that the mechanical properties of microparticles secreted by cells – vesicles 1–5 μm in di-
ameter – depends on the mechanical characteristics of the production cell culture environment.
Soft microparticles isolated from tumor cells (i.e., from cells cultured in a soft environment) led
to improved delivery of encapsulated doxorubicin in vivo.
In addition to improved targeting by using cell-derived receptors, natural systems also feature im-
mune-signaling ligands. For example, CD47 glycoprotein expressed on mammalian cell mem-
branes is a putative marker of 'self'. This signal is a 'don’t eat me' message to macrophages
and other phagocytes, and prevents an autoimmune reaction. By employing liposomes with D-
peptide CD47 mimicry, Tang and coworkers reported that these 'self'-labeled liposomes can448 Trends in Biotechnology, May 2021, Vol. 39, No. 5
Key Figure
Schematic Illustration Presenting the Bottom-Up Assembly of Multicompartment Lipid-Based Ves-
icles for Advanced Drug Delivery.
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Figure 2. By employing various microfluidic platforms, naturally inspired drug-delivery systems encapsulating various therapeutic cargos can be easily assembled from
elementary building blocks. This bottom-up engineering approach offers the possibility to incorporate enhanced biochemical functionalities into the drug carrier to
enable selective interaction with disease-causing cells and efficient intracellular release of its therapeutic payload.
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OPEN ACCESSact as a mask by coating the hepatic phagocyte membrane. As a result, phagocytic clearance of
subsequently injected drug-loaded polymeric nanoparticles was significantly reduced [34]. Over-
all, this 'self' signaling mechanism showed potential to lower the MPS barrier for subsequently
injected drugs in vivo. Another example based on the assembly of EVs presenting various immu-
nological ligands involved immobilization of recombinant Fas ligand (FasL). FasL can induce tar-
get cell apoptosis by activating a Fas signaling cascade [35]. Yerneni and colleagues recently
applied this strategy by anchoring FasL in the lipid bilayer of cell-isolated EVs by means of
cholesterol-tagged DNA to selectively induce apoptosis of cancer cells upon interaction with
the FasL-bearing EVs [36].
These results highlight the combinatorial impact of physical properties (e.g., stiffness and size)
and biochemical properties (e.g., harboring various cell-derived ligands) on improving the
targeting and drug-delivery efficiency. These key features can be incorporated into drug-
delivery systems by using EVs as building blocks. However, EV extraction and isolation proce-
dures remain irreproducible, technically challenging, and time-consuming, and these obstacles
impede their broad clinical translation [37]. Moreover, in addition to selectively targeting specific
cells and evading the MPS, frontier drug-delivery systems will need to be able to sense and re-
spond to changes in their immediate environment during drug release – a property referred to
as intelligent and dynamic release of therapeutics. In sum, the principles of a bottom-up approach
can be implemented by the high-throughput generation of bioinspired multifunctional synthetic
systems with well-controlled biophysical and biochemical properties for advanced drug release.
Bottom-Up Assembly of Synthetic Cells as Advanced Drug-Delivery Systems
The modular engineering approach for the bottom-up assembly of synthetic cells can be
employed to construct more complex systems that can control the amount of cargo released
based on external physiological triggers (Box 3). Chen and colleagues developed an ingenious
synthetic β cell (AβC) that is capable of dynamic insulin secretion as a function of the extracellular
glucose concentration [38]. An interdigitation–fusion method of assembly was employed toTrends in Biotechnology, May 2021, Vol. 39, No. 5 449
Box 3. Synthetic Vesicles versus Synthetic Cells
In general terms, a synthetic vesicle may be defined as the sequestration of discrete volume (typically in the pico- to femto-
liter range) through the self-assembly of a physical boundary from fundamental building blocks. For instance, liposomes
and larger lipid vesicles employ lipids as elementary units to enclose constituents through the assembly of a lipid bilayer.
In addition to lipids, polymers, proteins, or even colloids may be employed as fundamental building block to generate var-
ious synthetic vesicles – respectively polymersomes, proteinosomes, and colloidosomes. Although their use must be tai-
lored to individual needs, their physicochemical properties can be meticulously engineered to tackle various
biotechnological challenges. In the field of drug delivery, these synthetic vesicles typically encapsulate therapeutic drugs,
transport their cargo, and release their payload upon endogenous or exogenous stimulation once the designated site is
reached. Various biochemical ligands and chemical functionalities are incorporated into the synthetic vesicles to confer
sensitivity and selectivity. However, despite advances in the generation of complex architecture, synthetic vesicles all face
the same challenge: lack of dynamics and feedback, or, in other words, an inability to adapt the release of therapeutics as a
function of local environmental changes.
A synthetic cell – also referred as a protocell – is a minimalistic replicate of a living cell that attempts to mimic key cellular
functionalities by enclosing biological machinery in a cell-like compartment. These functions may imply (i) continuous en-
ergy and biomaterial harvesting or genesis to sustain metabolic activities, (ii) compartmentalization to isolate distinct re-
agents and/or to perform independent intraluminal reactions, (iii) the capacity to growth and divide, (iv) sensing and
communication with the immediate surroundings, and finally (v) motility [85]. In contrast to synthetic vesicles, synthetic cells
enable the introduction of feedback mechanisms – or dynamics – by encapsulating various biological machineries to ad-
dress tasks that cannot be achieved by simple synthetic vesicles. For instance, synthetic cells are able to autonomously
harvest molecular components from their extracellular environment to sustain their own energy production [86].
Empowered by compartmentalization of the system, molecular cargos can be spatially isolated and released in response
to physicochemical changes in the vicinity of the synthetic cell. Consequently, by applying these synthetic cells to drug de-
livery, dynamic release of therapeutics can be achieved for smarter drug therapy.
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somes (Figure 3A). Upon exposure to high extracellular glucose concentrations, glucose enters
the synthetic AβC through the membrane-incorporated recombinant GLUT2 importer protein.
Once inside, glucose degradation by glucose oxidase begins. This degradation process leads
to a decrease in pH inside the GUV lumen, which in turn unshields the insulin-loaded liposomes.
Once exposed, peptide K can associate with peptide E, which is located inside the lipid mem-
brane of the homing GUV. This reaction triggers the secretion of insulin mediated by recombinant
SNARE proteins. The AβC has an impressive ability to regulate blood glucose levels in vivo in a
streptozotocin (STZ)-induced type 1 diabetic mouse model. A second example was recently
published by Krinsky and coworkers. The researchers encapsulated a cell-free protein system
in GUVs to directly express and release Pseudomonas exotoxin A into their immediate surround-
ings [39]. By taking advantage of essential building blocks in their local environment, such as ATP,
GTP, UTP, and amino acids, the GUV-based therapeutic synthetic cells could autonomously pro-
duce and release Pseudomonas exotoxin A (Figure 3B). The released toxin induced the efficient
killing of cancer cells in vitro, and also in vivo when the GUVs were directly injected intratumorally
into BALB/c mice bearing orthotopic 4T1 tumors. Interestingly, the therapeutic synthetic cell ex-
hibited higher toxicity than purified toxin. This may be attributed to the improved stability of the
protein expressed directly in the synthetic cells or possibly to the prolonged release of protein
in disease-causing cells. This novel platform, which merges synthetic biology and drug delivery
with elegance, highlights the potential of cell-like advanced carriers to directly synthesize thera-
peutics at the disease site. Moreover, Hindley and colleagues reported bottom-up assembly of
calcium-sensitive GUVs (Figure 3C). These were used for the release of low molecular weight
compounds, such as calcein loaded within small unilamelar vesicles, in response to exogenous
calcium influx [40].
In addition to the ability to sense and react to their local environment, advanced drug-delivery sys-
tems will need to overcome several barriers (see section on Drug-delivery Challenges: Opportu-
nities for Bottom-Up Synthetic Biology). This will requiremechanical stability, energetic autonomy,450 Trends in Biotechnology, May 2021, Vol. 39, No. 5
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OPEN ACCESSand the possibility of external control. By co-reconstituting photosystem II and proteorhodopsin
with ATP synthase, Lee and coworkers created proteoliposomes that can dynamically facilitate
ATP synthesis steered by independent photoactivation [41]. These photosynthetic organelles
were subsequently encapsulated inside GUVs and were used to activate F-actin polymerization
upon illumination with red light to achieve local membrane deformation without rupture. The F-Trends in Biotechnology
(See figure legend at the bottom of the next page.)
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dition, Weiss and colleagues reported the reconstitution of ATP synthase directly inside the GUV
membrane to produce ATP controlled by an external pH gradient [26]. They also showed that se-
quentially assembled GUV-based synthetic cells were capable of sensing and responding to the
extracellular environment by creating specific interactions with the extracellular matrix via trans-
membrane integrin proteins (Figure 3D) to reconstitute an F-actin cortex (Figure 3E). These syn-
thetic cells showcase the potential of the bottom-up approach to engineer complex systems that
are sensitive to external stimuli such as light and/or pH to provide energy-independence and to
create specific interactions with their extracellular environment.
Microfluidic Generation of Micro-Scale and Multicompartment Synthetic Cells
The key advantages of bottom-up synthetic biology lie in the modularity and intercompatibility of
the methods of synthesis. By means of droplet-based microfluidic platforms (Box 2), various
compartments can be independently assembled by three distinct methods: charge-mediated as-
sembly, emulsion phase transfer, and double-emulsion. Each method offers unique advantages.
Charge-mediated assembly provides the ability to generate GUVs with various lipid composi-
tions, thus enabling the fine-tuning of physicochemical properties such as surface charge, stiff-
ness, and fluidity [26,42]. Moreover, it allows the encapsulation of precise amounts of
biologically active small molecules, permits the reconstitution of transmembrane proteins into
the lipid envelope, and enables controlled assembly of multicompartment systems
[20,26,42,43]. Emulsion phase transfer enables the formation of an asymmetric lipid bilayer
[44], the direct isolation of vesicles in aqueous medium, and does not require the use of dewetting
surfactants or solvent extraction step [40,45–48]. Moreover, this method can encapsulate com-
plex protein machinery [39]. This is an advantage over charge-mediated assembly because it
could potentially impede small unilamelar vesicles fusion to the droplet periphery. The double
emulsion-based method also allows the generation of asymmetric lipid vesicles [49,50]. It is
also compatible with organic solvents in glass capillary microfluidic devices, which are typically in-
compatible with poly(dimethylsiloxane) (PDMS)-based devices [51]. Importantly, double-
emulsion methods allow the flexible assembly of a multicompartment system either through suc-
cessive encapsulation of the vesicles generated or through the coencapsulation of distinct vesi-
cles [52]. A summary of the respective methods is presented in Table 1.
Notably, in the case of double emulsion-based methods, the addition of a specific surfactant to
the outer aqueous phase promotes dewetting (i.e., the spontaneous removal of excess oil sur-
rounding the inner aqueous core). This strategy enables the total elimination of potential residual
oil pockets that can affect the stability of the vesicles. Deng and coworkers reported the use of
Pluronic® F68 surfactant to initiate and promote the dewetting of chloroform/hexane residual
oil in a capillary-based microfluidic system [51–54]. Nonetheless, the use of chloroform as anFigure 3. Bottom-Up Assembly of Synthetic Cells That Mimic Key Cellular Functionalities. (A) Schematic depicting the biochemical processes inside an artificial
β cell (AβC). Letter in square brackets indicates the concentration. The inset shows a cryo-scanning electron microscopy (cryo-SEM) micrograph of multicompartment
assembly (scale bar, 5 μm). Image adapted, with permission, from [38]. (B) A synthetic cell encapsulating a cell-free protein system. By sourcing essential nutrients
such as nucleotides and amino acids from the extracellular environment, the synthetic cell can sustain independent synthesis of the therapeutic protein. Image
adapted, with permission, from [39]. (C) A giant unilamellar vesicle encapsulating mechanosensitive liposomes and secretory phospholipase A2 (sPLA2). The liposome
contains reconstituted mechanosensitive channels of large conductance (MscL). Ca2+ influx into the nested vesicles through α-hemolysin pores activates the
conversion of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) lipids to their 1-oleoyl-2-hydroxy-glycero-3-phosphocholine (lyso-PC) form by sPLA2. This conversion
results in local mechanical deformation of the liposomes situated inside the vesicle and ultimately leads to the release of their content. Image adapted, with permission,
from [40]. (D) Reconstitution of αIIbβ3 integrin into giant unilamellar vesicles that exhibit selective interaction with fibrinogen-coated glass, demonstrating the ability of a
synthetic cell to maintain the function and activity of reconstituted proteins. (E) Actin cytoskeleton containing a synthetic cell. Images adapted, with permission, from
[26]. Abbreviations: BSA, bovine serum albumin; CAT, catalase; CFPS, cell-free protein synthesis; GFP, green fluorescent protein; GOx, glucose oxidase; N.C.,
negative control referring to synthetic cells with all required components, but excluding the DNA template.
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Table 1. Current Methods for High-Throughput Generation of Micron-Sized Lipid Vesiclesa
Method Possible lipid composition Multicompartment
generation
Suitable for charged lipids Use of
surfactant?b
Refs
Interdigitation-fusion DPPC Liposomes Not mentioned No [38,87–89]
Emulsion phase
transfer




Egg PC, DOPC, DPPC, and Ch Liposomes or
coacervates












DOPC, DOPE, DOPS, egg PC, egg









Electroformation PC-rich lipids and Ch Lipo- and
proteoliposomes
Up to 20 mol% anionic lipid No [41,93]
aAbbreviations: Ch, cholesterol; DOBAQ, N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-1-aminium; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine;
DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOPG, 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol); DOPS, 1,2-dioleoyl-sn-glycero-3-phospho-L-ser-
ine; DOTAP, 1,2-dieleoyl-3-trimethylammonium-propane; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; GUVS, giant unilamellar vesicles; PC, phosphocholine;
PFO, 1H,1H,2H,2H-perfluoro-1-octanol; PDMS, poly(dimethylsiloxane); PG, phosphatidylglycerol; POPC, 1-palmotoyl-2-oleoyl-glycero-3-phosphocholine; W/O/W, wa-
ter/oil/water.
bThe surfactant was employed for one of the following reasons: to promote/initiate dewetting, stabilize the resulting GUVs once released into the aqueous phase, or enable
transfer from the oil phase to the water phase.
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partial water solubility [55]. By using an oil phase that is both compatible with PDMS-based
microfluidics and has minimal solubility in water, Deshpande and colleagues employed high con-
centration of poloxamer 188 (i.e., Pluronic® F68) to promote the fast dewetting of excess octanol
[56,57]. Referred to as octanol-assisted liposome assembly (OLA), this double emulsion-based
method enables the high-throughput generation of small GUVs (down to 5 μm in diameter) di-
rectly on a chip. Although featuring clear advantages, these recent platforms rely on the use of
an outer aqueous mixture of high viscosity, such as glycerol:water or polyvinyl alcohol:polyethyl-
ene glycol:water. These aqueous phases impede the use of centrifugation as a purification
method. As an alternative, Krafft and coworkers developed a simplified system relying solely on
sucrose/salt solution as the inner and outer aqueous phases [58]. To completely dewet theBox 4. Droplet-Based Microfluidics for the Assembly of Advanced Molecular Systems
In contrast to conventional microfluidics, which involve the continuous flow of various fluids in a laminar flow regime (i.e.,
low Reynolds number), droplet-based microfluidics allows the manipulation of discrete volumes through the generation
of emulsions such as water-in-oil (W/O) or oil-in-water (O/W) droplets. These microdroplets can act as independent
picoliter reactors and have found numerous applications in various scientific fields.
Droplet-based microfluidics features various functional units: a droplet production unit to encapsulate a variety of chemical
and biochemical contents [26]; a pico-injector for the sequential injection of picoliter volumes into individually produced
droplets [94]; a fusion module to provoke the fusion of two distinct droplets, thus enabling the mixture of various chemical
and biochemical reagents with high temporal control [95]; a mixing module to improve convection and thereby facilitate
molecular reactions within the droplet [96]; a sorting module to precisely separate individual droplets based on various an-
alytical signals such as fluorescence [62] or mass spectrometry [97]; a releasing unit to liberate the entrapped mixture from
the droplet into an aqueous continuous phase by applying an electrical field [98] or by using a passive trapping structure
[26]; and a detection or observation module that facilitates the assessment of a large droplet population [43,99]. Adding to
the various possibilities of droplet-based microfluidics, capillary microfluidics – which in contrast to PDMS-based
microfluidics uses glass capillaries – is even compatible with the use of organic solvent [52]. Capillary microfluidics is there-
fore ideally suited to generate both simple and complex emulsions [100].
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Outstanding Questions
How can we generate synthetic
systems whose functional complexity
is comparable to that of living
systems? More specifically, how can
we further tailor these systems
towards advanced drug-delivery
applications?
Can bottom-up synthetic biology help
to create a fully synthetic EV?
Moreover, would these synthetic
vesicles exhibit similar biological
properties and induce similar cellular
responses as natural vesicles?
Can both bottom-up synthetic biology
and microfluidics personalize therapy
for individual patients by rapid and
reliable re-engineering of therapeutic
vehicles?
The use of surfactants to stabilize
GUVs seems to be essential to
maintain their integrity and prevent
their uncontrolled rupture in aqueous
environments. Can alternative lipid
compositions, or even fully synthetic
lipids, palliate the need for surfactants
and thus circumvent their use?
Can these microfluidic platforms be
incorporated into current industrial
pipelines for large-scale production of
advanced therapeutic carriers?
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OPEN ACCESSwater/oil/water double emulsion, their approach relied solely on an osmotic gradient generated
by encapsulation of sucrose at concentrations lower than the outer phase, thus rendering it pos-
sible to use centrifugation to purify the obtained GUVs. Nevertheless, most double emulsion-
based methods have an inherent drawback: adsorption of surfactant molecules onto the lipid bi-
layer. This concomitant adsorption is likely to affect membrane dynamics and mechanical prop-
erties. For instance, in the case of capillary-based microfluidics, the proportion of Pluronic® F68
molecule adsorbed on a liposome surface was approximated to follow a ratio of 1 mol surfactant
to 17 mol lipids [51]. Thus, the impact of the adsorbed surfactant on the mechanical properties
and dynamics of the lipid bilayer will need to be addressed, especially with regards to possible
therapeutic applications. On a positive note, a recent study comparing GUVs produced by
OLA to those created by electroformation found that the presence of surfactant molecules during
OLA production only had a limited impact on the lateral diffusion of lipids in the GUV membrane
compared to membranes generated by electroformation [59].
Microfluidic platforms for micron-scale carrier assembly make it possible to minutely engineer
complex lipid-based vesicles, comprising multifunctional targeting and compartmentalization
modules, from the bottom-up (Box 4). Moreover, the available methods can be combined to
design advanced drug-delivery systems (Figure 4). This enables the usage of dedicated proto-
col for the encapsulation of hydrophobic/hydrophilic molecules, cells, and protein machineries
[46,60], or even short interfering RNA [61], but also to create compartments that exhibit com-
plex spatial arrangements such as inner and outer membrane leaflets that differ in composition
[49,50]. Protein machineries, for instance, can be encapsulated by applying emulsion phase
transfer [39], and other compartments such as proteoliposomes can be generated using a
charge-mediated lipid vesicle formation. Both methods can be supported by droplet-based
microfluidics and pico-injection to achieve high throughput and low polydispersity [26]. The
resulting individual compartments can then be assembled within a homing GUV by capillary
microfluidics, a method that allows the number and stoichiometric composition of individual
compartments to be finely tuned [52]. Finally, the enrichment and quality control of drug carriers
produced, that comprise the desired number and type of compartments, can then be per-
formed by using currently established microfluidic platforms such as fluorescence-activated
droplet sorting [62].
Concluding Remarks
Nanomedicine has provided novel strategies for improving drug delivery towards specific patho-
gens and disease-causing cells. However, assembling these carriers requires exquisite control
over their chemical composition, structure, and functionalization with a multitude of biological li-
gands to achieve selective drug release. These engineering challenges thus require the develop-
ment of high-throughput, well-controlled, and novel platforms to manipulate both chemical and
biological constituents. Inspired by natural living systems, the design and development of ad-
vanced drug carriers with well-defined biophysical and biochemical properties can be facilitatedFigure 4. Engineering a Multicompartment Drug Carrier by Microfluidics. (A) Charge-mediated assembly of lipid-based vesicles. By using droplet-based
microfluidics, the aqueous phase containing small unilamellar vesicles (SUVs) and therapeutic cargo is entrapped within a water-in-oil (W/O) droplet. Addition of a
negatively charged surfactant to the oil phase promotes SUV fusion with the periphery of the droplet in the presence of Mg2+. This process enables the assembly of a
micron-scale vesicles that entrap the drug cargo (i). Following their generation, membrane proteins may be incorporated into the lipid bilayer by introducing
proteoliposomes by pico-injection (ii). The vesicles can then be releases into the physiological environment where their physicochemical and biochemical properties can
be assessed (iii). (B) Emulsion phase transfer allows encapsulation of large and complex protein machinery through the generation of a water-in-oil emulsion, where
herein, the oil phase is supplemented with lipids of the desired composition (i). The emulsion can then be layered onto a lipid monolayer formed beforehand at the
water/oil interface (ii). By applying centrifugation forces, the W/O droplets migrate to the lower aqueous phase, enabling the generation of a full lipid bilayer (iii). (C)
These two approaches enable the generation of distinct functional lipid-based vesicles that act as inner compartments (i). These inner compartments can then be
encapsulated, at the desired stoichiometry, by the use of capillary microfluidics (ii) to achieve the assembly of a multicompartment drug carrier (iii).
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key cellular functionalities – such as extracellular sensing, intracellular protein synthesis, and dy-
namic release of small molecules – novel carriers can achieve dynamic release of therapeutics.
Moreover, empowered by microfluidics, the precise and sequential assembly of multifunctional
multicompartment systems can be achieved with unprecedented control (see Outstanding
Questions).
By focusing on creating stimulus-responsive multicompartment systems, the order of release and
the properties of the molecular cargo can be engineered to allow sequential on-site release that
maximizes therapeutic benefits. In addition, multicompartment systems make it possible to en-
capsulate entities dedicated to preparing the cellular environment before the release of a thera-
peutic, another step towards optimizing therapeutic outcome. For example, Zinger and
coworkers recently encapsulated collagenase inside liposomes, resulting in so-called
collagozomes. These were used to dissemble extracellular matrices as a means to improve
drug penetration of subsequently injected therapeutics [63]. Collagozomes were applied to de-
grade the dense collagen stroma typically found in pancreatic ductal adenocarcinoma, followed
by injection of paclitaxel micelles. This strategy led to a significant reduction in the level of fibrotic
tissue surrounding the tumor. Simultaneously, improved drug penetration – assessed by size re-
duction of the pancreatic ductal adenocarcinoma tumors – was observed. Supported by these
recent innovations, we envisage that the sequential release of various inner compartments can
promote and facilitate a potential hierarchical targeting, from primary to tertiary, resulting in overall
improved intracellular delivery of therapeutics.
Nevertheless, the toxicity and the clinical benefits of multicompartment-based drug carriers has
not yet been assessed. The use of microfluidics to produce and assemble these advanced car-
riers will likely facilitate such assessments by allowing unprecedented control over size, reproduc-
ibility, and throughput. Cytotoxicity investigations will be essential, especially when microfluidic
platforms rely on surfactant to either stabilize GUVs or initiate a dewetting process. The evaluation
of the absolute amount of surfactant and the impact of the mechanical properties of the lipid bi-
layer, such as rigidity, fluidity, and stiffness, need to be investigated. This is especially true be-
cause softer materials have been shown to improve drug penetration. Furthermore, the nature
of these surfactants may compromise clinical translation. Charge-mediated assembly of
multicompartment systems using novel synthetic fluorosurfactants will surely offer interesting al-
ternatives to double emulsion-based methods of assembly.
Taken together, the pharmacokinetics of micron-sized lipid-based carriers should be investigated
in greater detail because they could not only transport considerably larger drug quantities, but
also deliver drugs that are larger in size. The past decades of pharmacological research have gen-
erated ever more complex and larger therapeutics, ranging from low molecular weight com-
pounds [64] to supramolecular antibodies [65] and therapeutic viruses [66]. In addition,
because larger delivery systems carry increased drug quantities, they are also more likely to func-
tion as durable drug reservoirs in the target tissue, thereby improving the longevity of future bio-
medical applications. This emphasizes the need to create larger vehicles that have sufficient
cargo capacity for next-generation therapeutics. The possibility to engineer ever more complex
systems inspired by living cells provides a framework for the development of carriers whose func-
tional diversity is comparable to that of cells. For instance, several immunological cells possess
the ability to identify, interact with, and eventually kill specific targets. They subsequently take
up target leftovers to carry them to lymph nodes for presentation and conditioning of other im-
mune cells. Similarly, we foresee systems that combine complex therapeutics and diagnostic
functionalities, each isolated inside specific inner compartments, in a single vesicle. Such a456 Trends in Biotechnology, May 2021, Vol. 39, No. 5
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OPEN ACCESStheranostic vesicle could be engineered to identify patient-specific targets, unload their molecular
cargo, and afterwards take a 'molecular biopsy'. The theranostic vesicle could directly transduce
an analytical signal in vivo or could be collected from the body fluids of the patients for further di-
agnostic and treatment-evaluation procedures. Such a drop-off/pick-up system for automated
storage and retrieval at the micron-scale could transform modern medicine.
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